Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9Y5W7
UPID:
SNX14_HUMAN
Alternative names:
-
Alternative UPACC:
Q9Y5W7; B4DI55; Q4VBR3; Q5TCF9; Q5TCG0; Q6NUI7; Q6PI37; Q9BSD1
Background:
Sorting nexin-14 (SNX14) is a pivotal protein that plays a crucial role in maintaining neuronal excitability and synaptic transmission. It is involved in intracellular trafficking and is essential for autophagosome clearance, facilitating the fusion of lysosomes with autophagosomes. SNX14 specifically binds to phosphatidylinositol 3,5-bisphosphate, a key component of late endosomes/lysosomes, highlighting its significance in cellular processes.
Therapeutic significance:
SNX14's mutation is directly linked to Spinocerebellar ataxia, autosomal recessive, 20 (SCAR20), characterized by cerebellar atrophy, ataxia, and intellectual disability. Understanding the role of Sorting nexin-14 could pave the way for developing targeted therapies for SCAR20, offering hope for patients suffering from this debilitating condition.